Ampio Pharmaceuticals, Inc. States That Its Policy is Not to Comment on Unusual Market Activity

GREENWOOD VILLAGE, Colo., Oct. 25, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it was contacted by the New York Stock Exchange in light of unusual market activity in the Company's common stock on Thursday, October 24, 2013. In accordance with the New York Stock Exchange's usual practice, the Company announced that its policy is not to comment on unusual market activity; however, the management did summarize significant milestones achieved over the past ten weeks including:

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

• Positive results for Ampion in osteoarthritis of the knee clinical trial
• $25 million financing
• Positive summary data from Luoxis Diagnostics' study of traumatic brain injury patients and issuance of company's third US patent for its oxidation-reduction potential diagnostic platform
• Positive results from Independent Panel Review of the interim analysis of the Optina trial for diabetic macular edema

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statements
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to the completion, timing and size of the registered direct offering, as well as risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Rick Giles
Director of Investor Relations
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6530
Email: rgiles@ampiopharma.com

SOURCE Ampio Pharmaceuticals, Inc.